PSO is a common abbreviation for psoriasis, a chronic inflammatory skin condition that affects roughly 43 million people worldwide. It develops when the immune system mistakenly speeds up the growth cycle of skin cells, causing them to pile up on the surface faster than the body can shed them. The result is thick, scaly patches that can appear anywhere on the body but most often show up on the elbows, knees, scalp, and lower back.
What Happens in the Skin
In healthy skin, cells in the deepest layer gradually mature, lose their nucleus, and form the tough outer barrier you can see and touch. This renewal process is orderly and continuous. In psoriasis, immune cells called Th17 cells release signaling molecules that act directly on skin cells, pushing them to multiply far faster than normal. The cells don’t have time to fully mature before they reach the surface, so they stack up with their nuclei still intact, a process pathologists call parakeratosis.
This creates a self-reinforcing loop. The rapidly multiplying skin cells release their own chemical signals that recruit even more immune cells to the area, which in turn drive more skin cell growth. That cycle of immune activation and skin overproduction is why psoriasis persists and flares rather than healing on its own. It also explains why the condition is systemic: the inflammation isn’t limited to the skin but circulates throughout the body.
Types of Psoriasis
The most common form, plaque psoriasis, accounts for the vast majority of cases. It appears as raised, reddish patches with sharp borders covered by silvery-white scales. These plaques tend to show up symmetrically, meaning if one elbow is affected, the other usually is too.
- Guttate psoriasis produces small, droplet-shaped spots that appear suddenly, often after a streptococcal throat infection. They tend to scatter across the trunk, upper arms, thighs, face, and scalp.
- Inverse psoriasis develops in skin folds like the armpits, groin, and under the breasts. Because friction and moisture prevent scales from forming, these lesions look like smooth, bright red patches with clear edges.
- Palmoplantar psoriasis affects the palms and soles symmetrically. Redness may be subtle, appearing pinkish-yellow, but the skin becomes very thick and can crack painfully.
- Erythrodermic psoriasis is a rare, serious form where inflammation covers roughly 80% or more of the body surface. The typical plaques lose their distinct borders, and widespread redness replaces the usual patchy appearance.
Causes and Genetic Risk
Psoriasis runs in families, though having a relative with the condition doesn’t guarantee you’ll develop it. One of the strongest genetic links involves a specific immune system gene variant called HLA-Cw6. People who carry this variant not only face a higher risk of developing psoriasis but tend to develop it earlier in life. In one study, carriers developed symptoms at an average age of about 26, compared to 32 for non-carriers. Those who develop psoriasis before age 21 are especially likely to carry this genetic marker.
Genetics alone don’t cause psoriasis, though. The condition requires an environmental trigger to activate the immune response in someone who is already predisposed.
Common Triggers for Flares
One of the more distinctive features of psoriasis is the Koebner phenomenon: new patches forming at sites of skin injury. A cut, sunburn, tattoo, surgical incision, or even prolonged pressure from a prosthetic limb can provoke new lesions in skin that was previously clear. Even minor trauma like scratching an itch can set it off.
Beyond skin injury, well-known flare triggers include streptococcal infections (particularly for guttate psoriasis), emotional stress, certain medications, cold and dry weather, heavy alcohol use, and smoking. Not everyone responds to the same triggers, so learning your personal pattern is one of the most practical steps in managing the condition.
Beyond the Skin: Psoriatic Arthritis and Other Risks
Psoriasis is not just a skin disease. Up to 41% of people with psoriasis develop psoriatic arthritis, a condition that causes joint pain, stiffness, and swelling. It can affect any joint but commonly targets the fingers, toes, lower back, and knees. In large database studies, about 8% of psoriasis patients had a documented diagnosis of psoriatic arthritis at any given time, with new cases developing at a rate of roughly 1% per year.
People with psoriasis also carry higher rates of conditions linked to metabolic syndrome. In one analysis of nearly 49,000 psoriasis patients, 62% had high blood pressure, about 50% had lipid disorders, and 31% were classified as overweight or obese. Back pain affected over 73% of psoriasis patients. These numbers reflect the systemic nature of the inflammation driving the disease, not just coincidence. The chronic inflammatory state that fuels skin symptoms also stresses the cardiovascular system and metabolic pathways. Depression and other mood disorders are also more common.
How Severity Is Measured
Doctors assess psoriasis severity using a tool called the Psoriasis Area and Severity Index, or PASI. It divides the body into four regions (head, trunk, upper limbs, and lower limbs) and scores each for redness, thickness, and scaling on a 0 to 4 scale, along with the percentage of skin affected. The final score ranges from 0 to 72, with higher numbers indicating more severe disease. In clinical practice and research, a PASI score helps determine whether someone qualifies for advanced treatments and tracks how well those treatments are working.
Treatment Options
Mild psoriasis is typically managed with topical treatments applied directly to the skin, including corticosteroid creams, vitamin D analogues, and moisturizers. For moderate cases, phototherapy (controlled exposure to ultraviolet light) can slow skin cell turnover and reduce inflammation.
The biggest shift in psoriasis treatment over the past two decades has been the development of biologic therapies for moderate to severe disease. These are injectable medications that target specific parts of the immune cascade rather than suppressing the immune system broadly. Two classes have proven particularly effective. Drugs targeting the IL-17 pathway block a key signaling molecule produced by the Th17 cells that drive skin cell overproduction. Drugs targeting IL-23 go one step upstream, blocking the signal that activates those Th17 cells in the first place.
Both classes achieve substantial skin clearance. In large clinical trials, patients treated with IL-17 or IL-23 inhibitors commonly reach 75% or 90% improvement in their PASI scores, with low rates of serious side effects. Many patients achieve nearly clear or completely clear skin for the first time in years. These treatments are given as injections, typically every few weeks to every few months depending on the specific medication, and require ongoing use to maintain results.
For people who don’t respond to or can’t access biologics, older systemic medications taken by mouth remain an option. The choice of treatment depends on the severity and type of psoriasis, which joints or body areas are involved, and whether psoriatic arthritis is also present.